Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 16 October 1992:
Vol. 258. no. 5081, pp. 447 - 451
DOI: 10.1126/science.1411538
Prev | Table of Contents | Next

Articles

Science, Vol 258, Issue 5081, 447-451
Copyright © 1992 by American Association for the Advancement of Science

articles

Neural computing in cancer drug development: predicting mechanism of action

JN Weinstein, KW Kohn, MR Grever, VN Viswanadhan, LV Rubinstein, AP Monks, DA Scudiero, L Welch, AD Koutsoukos, AJ Chiausa, and al. et

Laboratory of Mathematical Biology, National Cancer Institute, Bethesda, MD 20892.

Described here are neural networks capable of predicting a drug's mechanism of action from its pattern of activity against a panel of 60 malignant cell lines in the National Cancer Institute's drug screening program. Given six possible classes of mechanism, the network misses the correct category for only 12 out of 141 agents (8.5 percent), whereas linear discriminant analysis, a standard statistical technique, misses 20 out of 141 (14.2 percent). The success of the neural net indicates several things. (i) The cell line response patterns are rich in information about mechanism. (ii) Appropriately designed neural networks can make effective use of that information. (iii) Trained networks can be used to classify prospectively the more than 10,000 agents per year tested by the screening program. Related networks, in combination with classical statistical tools, will help in a variety of ways to move new anticancer agents through the pipeline from in vitro studies to clinical application.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.
M. Okabe, G. Szakacs, M. A. Reimers, T. Suzuki, M. D. Hall, T. Abe, J. N. Weinstein, and M. M. Gottesman (2008)
Mol. Cancer Ther. 7, 3081-3091
   Abstract »    Full Text »    PDF »
In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation.
O. N. Ikediobi, M. Reimers, S. Durinck, P. E. Blower, A. P. Futreal, M. R. Stratton, and J. N. Weinstein (2008)
Mol. Cancer Ther. 7, 1337-1346
   Abstract »    Full Text »    PDF »
STITCH: interaction networks of chemicals and proteins.
M. Kuhn, C. von Mering, M. Campillos, L. J. Jensen, and P. Bork (2008)
Nucleic Acids Res. 36, D684-D688
   Abstract »    Full Text »    PDF »
Drug Sensitivity Prediction by CpG Island Methylation Profile in the NCI-60 Cancer Cell Line Panel.
L. Shen, Y. Kondo, S. Ahmed, Y. Boumber, K. Konishi, Y. Guo, X. Chen, J. N. Vilaythong, and J.-P. J. Issa (2007)
Cancer Res. 67, 11335-11343
   Abstract »    Full Text »    PDF »
Evaluation of Action Mechanisms of Toxic Chemicals Using JFCR39, a Panel of Human Cancer Cell Lines.
N. Nakatsu, T. Nakamura, K. Yamazaki, S. Sadahiro, H. Makuuchi, J. Kanno, and T. Yamori (2007)
Mol. Pharmacol. 72, 1171-1180
   Abstract »    Full Text »    PDF »
Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part VII: Why Not Start with a Single Test: A Transformational Alternative to Genotoxicity Hazard and Risk Assessment.
W. W. Ku, J. Aubrecht, R. J. Mauthe, R. H. Schiestl, and A. J. Fornace Jr (2007)
Toxicol. Sci. 99, 20-25
   Abstract »    Full Text »    PDF »
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study.
U. T. Shankavaram, W. C. Reinhold, S. Nishizuka, S. Major, D. Morita, K. K. Chary, M. A. Reimers, U. Scherf, A. Kahn, D. Dolginow, et al. (2007)
Mol. Cancer Ther. 6, 820-832
   Abstract »    Full Text »    PDF »
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
O. N. Ikediobi, H. Davies, G. Bignell, S. Edkins, C. Stevens, S. O'Meara, T. Santarius, T. Avis, S. Barthorpe, L. Brackenbury, et al. (2006)
Mol. Cancer Ther. 5, 2606-2612
   Abstract »    Full Text »    PDF »
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
P. L. Lorenzi, W. C. Reinhold, M. Rudelius, M. Gunsior, U. Shankavaram, K. J. Bussey, U. Scherf, G. S. Eichler, S. E. Martin, K. Chin, et al. (2006)
Mol. Cancer Ther. 5, 2613-2623
   Abstract »    Full Text »    PDF »
Spotlight on molecular profiling: "Integromic" analysis of the NCI-60 cancer cell lines.
J. N. Weinstein (2006)
Mol. Cancer Ther. 5, 2601-2605
   Full Text »    PDF »
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel..
K. J. Bussey, K. Chin, S. Lababidi, M. Reimers, W. C. Reinhold, W.-L. Kuo, F. Gwadry, Ajay, H. Kouros-Mehr, J. Fridlyand, et al. (2006)
Mol. Cancer Ther. 5, 853-867
   Abstract »    Full Text »    PDF »
Effects of a series of organosulfur compounds on mitotic arrest and induction of apoptosis in colon cancer cells.
D. Xiao, J. T. Pinto, G. G. Gundersen, and I. B. Weinstein (2005)
Mol. Cancer Ther. 4, 1388-1398
   Abstract »    Full Text »    PDF »
ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma.
N. Y. Frank, A. Margaryan, Y. Huang, T. Schatton, A. M. Waaga-Gasser, M. Gasser, M. H. Sayegh, W. Sadee, and M. H. Frank (2005)
Cancer Res. 65, 4320-4333
   Abstract »    Full Text »    PDF »
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
N. Nakatsu, Y. Yoshida, K. Yamazaki, T. Nakamura, S. Dan, Y. Fukui, and T. Yamori (2005)
Mol. Cancer Ther. 4, 399-412
   Abstract »    Full Text »    PDF »
Determination of Genes Related to Gastrointestinal Tract Origin Cancer Cells Using a cDNA Microarray.
T. M. Kim, H. J. Jeong, M. Y. Seo, S. C. Kim, G. Cho, C. H. Park, T. S. Kim, K. H. Park, H. C. Chung, and S. Y. Rha (2005)
Clin. Cancer Res. 11, 79-86
   Abstract »    Full Text »    PDF »
Membrane Transporters and Channels: Role of the Transportome in Cancer Chemosensitivity and Chemoresistance.
Y. Huang, P. Anderle, K. J. Bussey, C. Barbacioru, U. Shankavaram, Z. Dai, W. C. Reinhold, A. Papp, J. N. Weinstein, and W. Sadee (2004)
Cancer Res. 64, 4294-4301
   Abstract »    Full Text »    PDF »
Karyotypic Complexity of the NCI-60 Drug-Screening Panel.
A. V. Roschke, G. Tonon, K. S. Gehlhaus, N. McTyre, K. J. Bussey, S. Lababidi, D. A. Scudiero, J. N. Weinstein, and I. R. Kirsch (2003)
Cancer Res. 63, 8634-8647
   Abstract »    Full Text »    PDF »
Diagnostic Markers That Distinguish Colon and Ovarian Adenocarcinomas: Identification by Genomic, Proteomic, and Tissue Array Profiling.
S. Nishizuka, S.-T. Chen, F. G. Gwadry, J. Alexander, S. M. Major, U. Scherf, W. C. Reinhold, M. Waltham, L. Charboneau, L. Young, et al. (2003)
Cancer Res. 63, 5243-5250
   Abstract »    Full Text »    PDF »
The Application of Artificial Neural Network (ANN) Technique to Formulation Design of Flame Retardant Polymers--II. Halogen-Free Flame Retardant Polymeric Composites.
J. Xia, J. Wang, and C. Huang (2001)
Journal of Fire Sciences 19, 309-328
   Abstract »    PDF »
Thymidine Kinase, Thymidylate Synthase, and Dihydropyrimidine Dehydrogenase Profiles of Cell Lines of the National Cancer Institute's Anticancer Drug Screen.
J. L. Grem, K. D. Danenberg, K. Behan, A. Parr, L. Young, P. V. Danenberg, D. Nguyen, J. Drake, A. Monks, and C. J. Allegra (2001)
Clin. Cancer Res. 7, 999-1009
   Abstract »    Full Text »
Gadd45, a p53-Responsive Stress Protein, Modifies DNA Accessibility on Damaged Chromatin.
F. Carrier, P. T. Georgel, P. Pourquier, M. Blake, H. U. Kontny, M. J. Antinore, M. Gariboldi, T. G. Myers, J. N. Weinstein, Y. Pommier, et al. (1999)
Mol. Cell. Biol. 19, 1673-1685
   Abstract »    Full Text »    PDF »
A Nonclonogenic Cytotoxicity Assay Using Primary Cultures of Patient Tumor Cells for Anticancer Drug Screening.
S. Dhar, J. Gullbo, K. Nilsson, P. Nygren, and R. Larsson (1998)
J Biomol Screen 3, 207-216
   Abstract »    PDF »
Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster Analysis of Ellipticine Analogs with p53-Inverse and Central Nervous System-Selective Patterns of Activity.
L. M. Shi, T. G. Myers, Y. Fan, P. M. O'Connor, K. D. Paull, S. H. Friend, and J. N. Weinstein (1998)
Mol. Pharmacol. 53, 241-251
   Abstract »    Full Text »
Computer-Aided Screening: Myth, Magic, or Reality.
M. A. Collins (1996)
J Biomol Screen 1, 81-84
   Abstract »    PDF »
Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks.
A. J. Butte, P. Tamayo, D. Slonim, T. R. Golub, and I. S. Kohane (2000)
PNAS 97, 12182-12186
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)